Home » In The News » In rebuke to pharma, one-fifth of Bristol-Myers shareholders favor proposal tying pricing risks to executive pay In rebuke to pharma, one-fifth of Bristol-Myers shareholders favor proposal tying pricing risks to executive pay 02 May 2018 Stat News Share